



## **Press Release**

### **Eurocor announces 6 and 12 months interim results of the Freeway Stent Study at TCT Congress in San Francisco**

- **Freeway™ drug-coated balloon for treatment of stenotic or occluded lesions in the SFA or proximal popliteal arteries**

**Bonn, Germany – November 21, 2013** – [Eurocor GmbH](#), an Opto Circuits group company, unveiled 6 and 12 months insights of the ongoing Freeway Stent Study during the TCT Congress in San Francisco on October 29<sup>th</sup>. The study is lead-managed by Prof. Dr. Josef Tacke, Klinikum Passau, Germany. The multicenter, open, prospective randomized trial investigates the prevention of restenosis by the usage of a drug-coated balloon (DCB) Freeway or plain old balloon angioplasty (POBA) after Nitinol Stent implantation in the treatment of Superficial Femoral Artery (SFA) or Popliteal artery (PI-segment) lesions in the legs.

The randomized, prospective clinical study is being conducted in 15 European sites to investigate the rate of clinically driven target lesion revascularization (TLR). 200 patients suffering from *de novo* lesions that need to be stented will be enrolled and are randomized in a 1:1 ratio. Both groups will be treated with Nitinol stent implantation first following randomization in a 1:1 ratio to postdilatation with a drug-coated balloon (Freeway DCB) or a plain old balloon (POBA). During the 6<sup>th</sup> and 12<sup>th</sup> month, the patient will undergo a Duplex follow-up as well as an angiographic follow-up in a subgroup at 6 month. The analysis will be performed by an independent core lab.

#### **The Results at 6 and 12 months**

Currently 142 patients have been enrolled, whereof a 6 month follow-up is now available for 100 patients. 52 of them have been treated with a Nitinol stent and a DCB. The trend shows a very low target lesion revascularization (TLR) rate of 1,9% in the Freeway DCB group, whereas the second group of 48 patients that have been treated with the Nitinol stent and POBA are showing a TLR rate of 8,5%.

The 12 months FU results in 69 patients also shows a positive trend in the TLR rate of 5.7% for the DCB group (N=35) and 14.7% (N=34) for the POBA group.



## Conclusion

The TLR rate for the subgroup of patients treated with Freeway DCB shows a significant better outcome at 6 months and positive trend at 12 months for the patients. The results furthermore show a significant better clinical result regarding Rutherford Classification after stent postdilatation with Freeway DCB vs POBA after 6 and 12 months as well as a significant better primary patency rate with Freeway DCB compared to POBA at 6 months. Also the Ankle-Brachial-Index (ABI Index) shows a significant better clinical result for Freeway DCB compared to the POBA group at 6 months.

Prof. Dr. Josef Tacke commented: “In-stent restenosis is a serious problem in the SFA and PI-segment. Drug-coated balloons might be an option to prevent restenosis at an early stage for patients that need to be stented. The first insights are very promising and we are looking forward to the final results of the study.”

“The trend so far shows a good and safe performance of our drug-coated balloon Freeway. We trust that our DCB technology platform used in the Freeway Stent Study will offer better treatment options and significant therapeutic advantages for the patients,” said Dr. Rembert Pogge von Strandmann, Director Clinical Department, Eurocor.

## About Opto Circuits (India) Limited

Opto Circuits (India) Ltd. (OCI) is a vertically integrated multinational medical technology Group that specializes in primary, acute and critical care products for the global markets. Group companies such as [Cardiac Science](#), [Criticare](#), [Eurocor](#), [Mediaid](#), [AMD L](#) and [Unetixs Vascular](#) are leaders in vital signs monitors, emergency cardiac care equipment, vascular treatments and sensing technologies. Our USFDA listed and CE marked products are marketed in more than 150 countries and sold through direct and indirect sales channels across many emerging and developed economies. We’ve been ranked in Forbes’ Asia’s 200 Best under a Billion lists in 2008, 2009 and 2011. For more information, please visit [www.optoindia.com](http://www.optoindia.com).



## **About Eurocor GmbH**

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Europe. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group. For more information, please visit [eurocor.de](http://eurocor.de)

### **For Media Contact**

Opto Circuits (India) Ltd.

Media - [media@optoindia.com](mailto:media@optoindia.com)

Investors - [ir@optoindia.com](mailto:ir@optoindia.com)

+91 80 2852 1040-42

### Eurocor GmbH Press Office

Claudia Tischendorf

[pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)

+49 (0) 228 201 50 26